Ipsen and Skyhawk Foray Research Collaboration in Neurological Diseases

Ipsen, a worldwide biopharmaceutical organization, announced a worldwide collaboration with Skyhawk Therapeutics, a clinical-stage biopharmaceutical organization, to find and foster novel little particles that tweak RNA for intriguing neurological diseases. Under the terms of the agreement, Ipsen has the option to acquire a worldwide exclusive license for the development of successful development candidates (DC).

Once the DC nomination is approved, Ipsen will be in charge of everything. Skyhawk's unique platform accelerates the development of RNA-targeting small molecules in various therapeutic areas, including rare neurological diseases.

“We are delighted to join forces with the expert teams at Skyhawk, as we explore the potential for modifying RNA expression across rare and debilitating neurological conditions.” said Steve Glyman, SVP and head of neuroscience, research & development at Ipsen. “Our focus and expertise in movement disorders, and across our portfolio, is bringing best and first-in-class treatments to those with the highest unmet needs, now further fuelled by this novel platform at the cutting-edge of research.”

“Ipsen is an extraordinary company with a deep passion for serving patients, and we are excited to partner with them to expand their pipeline of innovative therapies,” said Sergey Paushkin, chief scientific officer at Skyhawk. “Our strategic partnership underscores our shared ambition to develop transformative medicines for people with rare neurological diseases for which there are no approved therapeutics.”

Under the partnership's provisions, Skyhawk is qualified to develop up to $1.8 billion in administrative and business achievements, including a forthright installment, for the choice and examination joint effort, in addition to potential for tiered eminences.